IP Library Granted Patent US 9,962,341
Granted Patent B2
US 9,962,341 · App. 15/321,766 · Granted May 8, 2018

Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer

Inventors: Colin Stott (Histon, GB); Marnie Duncan (Histon, GB); Thomas Hill (Histon, GB)
Assignee: GW Pharma Limited
A61K31/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,962,341
App. No.
15/321,766
Granted
May 8, 2018
Kind
B2
Abstract

The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).

Claims (9)

1. A method of treating melanoma comprising administering to a patient in need thereof an active pharmaceutical ingredient (API) comprising or consisting essentially of cannabidiol (CBD) and cannabigerol (CBG).

2. The method as claimed in claim 1 , wherein the CBD and CBG are present in a ratio of from 7.5:1 to 1:7.5 (CBD:CBG).

3. The method as claimed in claim 2 , wherein the CBD and CBG are present in a ratio of 7.5:1 to 2.5:1 (CBD:CBG).

4. The method as claimed in claim 2 , wherein the CBD and CBG are present in a ratio of about 5:1 (CBD:CBG).

5. The method as claimed in claim 2 , wherein the CBD and CBG are present in a ratio of 2:1 to 1:2 (CBD:CBG).

6. The method as claimed in claim 2 , wherein the CBD and CBG are present in a ratio of about 1:1 (CBD:CBG).

7. The method as claimed in claim 1 , wherein a dose of the API administered to the subject is between 1 and 1000 mg/kg day.

8. The method as claimed in claim 1 , wherein the API is administered as a pharmaceutical formulation comprising the API and one or more excipients.

9. The method as claimed in claim 8 , wherein the CBD is formulated for administration separately, sequentially or simultaneously with the CBG or the CBD and CBG are provided in a single dosage form.

Assignments (5)
SECURITY AGREEMENT Recorded Jul 22, 2021
From: GW PHARMA LIMITED; GW RESEARCH LIMITED
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 056958/0493 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER: 9685579 PREVIOUSLY RECORDED ON REEL 046609 FRAME 0822. ASSIGNOR(S) HEREBY CONFIRMS THE ASSET PURCHASE BY WAY OF DEED. Recorded Jan 30, 2019
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 048187/0401 →
ASSET PURCHASE BY WAY OF DEED Recorded Jul 23, 2018
From: GW PHARMA LIMITED
To: GW RESEARCH LIMITED
Reel/Frame 046609/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2018
From: STOTT, COLIN; DUNCAN, MARNIE; HILL, THOMAS
To: GW PHARMA LIMITED; OTSUKA PHARMACEUTICAL CO. LIMITED
Reel/Frame 045289/0152 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 20, 2018
From: OTSUKA PHARMACEUTICAL CO. LIMITED
To: GW PHARMA LIMITED
Reel/Frame 045289/0180 →
Priority Claims (1)
GB 1411465.6 · Jun 27, 2014 · national
Continuity (1)
Related Publication 20170143642A1 · May 25, 2017